Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

New York, New York 10021


RATIONALE: Melphalan and colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood. PURPOSE: Phase II trial to study the effectiveness of melphalan combined with filgrastim in stimulating peripheral stem cells in patients who have multiple myeloma.

Study summary:

OBJECTIVES: - Determine the safety and efficacy of melphalan when used with filgrastim (G-CSF) for stem cell mobilization in patients with multiple myeloma. - Analyze how this mobilization regimen affects parameters of stem cell (CD34+) mobilization and collection in these patients. - Determine how this mobilization regimen affects disease status and clonotypic (i.e., tumor cell) contamination in stem cell components in these patients. OUTLINE: Patients undergo peripheral blood stem cell (PBSC) mobilization consisting of melphalan IV on day 1 and filgrastim (G-CSF) subcutaneously beginning on day 2 and continuing until PBSC collection is complete. Patients are followed at 1 month. PROJECTED ACCRUAL: A total of 11-32 patients will be accrued for this study within 2 years.


DISEASE CHARACTERISTICS: - Diagnosis of multiple myeloma - Must have received induction therapy within the past 3 months - Chemoresponsive disease - Greater than 50% reduction of monoclonal paraprotein with reduction in marrow plasma cell infiltrate or greater than 50% reduction in marrow plasma cell infiltrate if disease is non-secretory - No symptomatic pleural effusions - Eligible for stem cell transplantation PATIENT CHARACTERISTICS: Age: - 18 and over Performance status: - ECOG 0-3 (ECOG 3 allowed only if due to bone disease or neuropathy) Life expectancy: - Not specified Hematopoietic: - Platelet count at least 150,000/mm^3 Hepatic: - Bilirubin no greater than 2.5 mg/dL Renal: - Creatinine no greater than 2.5 mg/dL OR - Creatinine clearance greater than 51 mL/min Cardiovascular: - No symptomatic cardiomyopathy - No medically documented symptomatic cardiac arrhythmias within the past 60 days - No New York Heart Association class III congestive heart failure - No myocardial infarction within the past 6 months Other: - No other concurrent medical conditions that would preclude study - No uncontrolled infections - No other active malignancy within the past 5 years except for non-melanoma skin cancer - Not pregnant - Negative pregnancy test - Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: - No prior stem cell mobilization or transplantation Chemotherapy: - See Disease Characteristics - No more than 200 mg prior oral melphalan Endocrine therapy: - Not specified Radiotherapy: - No more than 3000 cGy of prior radiotherapy for myeloma Surgery: - Not specified



Primary Contact:

Study Chair
Raymond L. Comenzo, MD
Memorial Sloan-Kettering Cancer Center

Backup Contact:


Location Contact:

New York, New York 10021
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.